The Bethlehem facility combines roasting, extraction, concentration, blending and packaging, adding hot and cold brew capabilities to Kerry’s US coffee operations.
Kerry’s Acrylerase enzyme has received a positive EFSA scientific opinion, supporting its use in reducing acrylamide levels in instant coffee and coffee substitute products across Europe.
Strong Americas and APMEA growth offset subdued European market conditions.
The new centre will strengthen Kerry’s Middle East footprint and accelerate sustainable food and beverage innovation through customer collaboration.
Kerry Group expands U.S. operations with a Pennsylvania coffee facility, adding jobs and boosting local supply chains.